STERIS Q3 revenue +9% to $1.5B; adj EPS $2.53 beats prior year $2.32; FY2026 outlook maintained

STERIS plc

2026-Q3 EPS reported $5.69 revenue$4,347,500,000

Revenue $1.5B (+9% YoY); constant currency organic revenue growth 8%.
Reported EPS from cont ops $1.96; adjusted EPS $2.53 vs $2.32 last year.
Healthcare revenue $1.1B (+9%), AST $286.6M (+11%), Life Sciences $145.8M (+7%).
Free cash flow first 9 months $737.6M vs $588.1M prior year period.
FY2026 adj EPS guidance reaffirmed $10.15-10.30; tariff headwind increased to ~$55M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.